Wortmannin

Drug Profile

Wortmannin

Latest Information Update: 01 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Eli Lilly; Nonindustrial source
  • Class Antineoplastics
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Graft-versus-host disease

Most Recent Events

  • 19 Jun 2001 This compound is still in active development
  • 18 Jun 2001 No-Development-Reported for Graft-versus-host disease in USA (Unknown route)
  • 28 Oct 1998 Preclinical development for Graft-versus-host disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top